Mostel Zachary, Rogers James Speed, Neogi Sushrita
Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, Elmhurst Hospital Center, NYC Health and Hospitals, New York, NY, USA.
J Glob Infect Dis. 2025 Feb 24;17(1):63-65. doi: 10.4103/jgid.jgid_150_24. eCollection 2025 Jan-Mar.
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome of immune dysregulation that results in multiorgan failure; HIV and histoplasmosis are known triggers of HLH. A young patient with AIDS was found to have disseminated histoplasmosis and met criteria for HLH. Despite 10 days of treatment with liposomal amphotericin B, she developed shock and acute respiratory distress syndrome and ultimately died. The few reported cases of HLH due to histoplasmosis in AIDS offer a variety of treatment approaches. There have been successful outcomes combining amphotericin with chemotherapies for HLH. Targeted therapies for HLH may be considered on a case-by-case basis in the setting of concurrent disseminated histoplasmosis and HIV/AIDS.
噬血细胞性淋巴组织细胞增生症(HLH)是一种危及生命的免疫失调综合征,可导致多器官功能衰竭;已知HIV和组织胞浆菌病是HLH的触发因素。一名患有艾滋病的年轻患者被发现患有播散性组织胞浆菌病,并符合HLH的标准。尽管接受了10天的脂质体两性霉素B治疗,但她仍出现休克和急性呼吸窘迫综合征,最终死亡。少数报告的艾滋病患者因组织胞浆菌病导致HLH的病例提供了多种治疗方法。将两性霉素与治疗HLH的化疗药物联合使用已取得成功。在并发播散性组织胞浆菌病和HIV/AIDS的情况下,可根据具体情况考虑针对HLH的靶向治疗。